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Abstract
Purpose—Antibodies specific for inhibitory checkpoints PD-1 and CTLA-4 have shown 
impressive results against solid tumors. This has fueled interest in novel immunotherapy 
combinations to impact patients who remain refractory to checkpoint blockade monotherapy. 
However, how to optimally combine checkpoint blockade with agents targeting T cell 
costimulatory receptors such as OX40 remains a critical question.
Experimental Design—We utilized an anti-PD-1 refractory, orthotopically-transplanted 
MMTV-PyMT mammary cancer model to investigate the anti-tumor effect of an agonist anti-
OX40 antibody combined with anti-PD-1. Since PD-1 naturally aids in immune contraction after T 
cell activation, we treated mice with concurrent combination treatment versus sequentially 
administering anti-OX40 followed by anti-PD-1.
Results—The concurrent addition of anti-PD-1 significantly attenuated the therapeutic effect of 
anti-OX40 alone. Combination-treated mice had considerable increases in type 1 and type 2 serum 
cytokines and significantly augmented expression of inhibitory receptors or exhaustion markers 
CTLA-4 and TIM-3 on T cells. Combination treatment increased intratumoral CD4+ T cell 
proliferation at day 13, but at day 19 both CD4+ and CD8+ T cell proliferation was significantly 
reduced compared to untreated mice. In two tumor models, sequential combination of anti-OX40 
followed by anti-PD-1 (but not the reverse order) resulted in significant increases in therapeutic 
efficacy. Against MMTV-PyMT tumors sequential combination was dependent on both CD4+ and 
CD8+ T cells and completely regressed tumors in ~30% of treated animals.
*Corresponding author. Bernard.Fox@providence.org (B.A.F.), 4805 NE Glisan St., North Pavilion, 2N56, Portland, OR 97213, T: 
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Conclusions—These results highlight the importance of timing for optimized therapeutic effect 
with combination immunotherapies and suggest the testing of sequencing in combination 
immunotherapy clinical trials.
Keywords
Combination immunotherapy; Costimulation; Checkpoint blockade; T cells; Cytokines
Introduction
The potential for immunotherapy to improve outcomes of cancer patients, particularly 
through the combination of agents targeting immune inhibitory pathways, is becoming 
increasingly evident (1,2). Nonetheless, how to optimally combine the myriad of new 
immunotherapy agents currently being developed remains a major question in cancer 
research. Antibodies targeting the Programed Cell Death protein-1 (PD-1, CD279) receptor 
have made a major therapeutic impact on multiple types of solid tumors (3). Given relative 
low levels of reported toxicity combined with therapeutic efficacy, PD-1 pathway blockade 
is currently the building block for testing combinations with other immunotherapeutics. 
PD-1 is an inhibitory molecule upregulated after T Cell Receptor (TCR) engagement that 
normally plays a major role in immune contraction, leading T cells to exhaustion and 
apoptosis (3–5). Cancer, however, can use the PD-1 pathway to its advantage by expressing 
Programmed Death-Ligand 1 (PD-L1, B7-H1, CD274) on a tumor’s surface or inducing it 
on the surface of other tumor-associated immune cells like macrophages or dendritic cells to 
suppress an anti-tumor immune response, making the PD-1 receptor an attractive target for 
immunotherapeutic intervention (6,7). By blocking PD-1 or PD-L1, exhausted tumor-
specific effector T cells can then be reinvigorated to enhance their function (8).
OX40 (CD134 or TNFRSF4) is a TNF family costimulatory receptor that is also upregulated 
on T cells after TCR recognition of specific antigen (9,10). However when engaged with its 
ligand, OX40 stimulation results in enhanced proliferation, activation, differentiation, and 
survival (9,11,12). OX40 is expressed on activated, conventional CD4+ and CD8+ T cells 
and strongly expressed on CD4+FoxP3+ regulatory T (Treg) cells, and can also be 
upregulated shortly after re-activation of primed effector T cell (11,13). Agonist antibodies 
specific to OX40 can induce significant anti-tumor effects in preclinical models (14,15) and 
despite OX40 expression occurring mainly on CD4+ T cells, anti-tumor responses have been 
credited to both CD4+ and CD8+ cells (13,16). OX40 costimulation has also demonstrated 
enhanced preclinical anti-tumor effects when combined with anti-cytotoxic T-lymphocyte-
associated protein-4 (CTLA-4) and either adjuvants, vaccination, or radiation (17–19). 
Supported by this promising preclinical data, OX40 is currently being evaluated in clinical 
trials in a variety of solid tumors (20).
Breast cancer is the most commonly diagnosed cancer in women but conventional therapies 
such as radiation, chemotherapy, and targeted therapies like the anti-HER-2 drug 
trastuzumab (Herceptin) have led to significant improvements in patient survival rates over 
recent decades. Nevertheless, a substantial portion of patients remain refractory to these 
conventional treatments and over the last decade a multitude of preclinical studies 
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demonstrating immunotherapy-mediated tumor regression, including with anti-OX40 (14), 
has renewed interest in utilizing immunotherapies in breast cancer and spawned a variety of 
clinical trials. Adding to this interest, tumor-infiltrating lymphocytes (TIL) have been shown 
to associate with good clinical outcome (21) and response to therapy (22). PD-1 expression 
on TIL and PD-L1 expression on breast cancer tumors is associated with worse prognosis 
(23,24) and preliminary results of clinical trials with PD-1 blockade have produced objective 
responses in specific subsets of patients (25). However, overall responses have been modest 
(5–19%), leaving a majority of patients refractory to monotherapy. Breast cancer TIL can 
express OX40 (14,26) and polymorphisms in OX40L (CD252) have shown to be associated 
with breast cancer carcinogenesis (27), suggesting that antibodies targeting both OX40 and 
PD-1 could be effective when given in combination.
To address the potential for anti-tumor effects by combining immunotherapies that target 
both receptors, we employed orthotopically transplanted tumors from murine mammary 
tumor virus polyoma middle T (MMTV-PyMT) mice, a preclinical model of oncogene-
driven mammary cancer (28). This model resembles luminal human breast cancer and is 
infiltrated with myeloid and T cells (29), making it a strong candidate for immunotherapy 
with T cell-targeting antibodies. Here we report that this model is refractory to PD-1 
blockade, but by stimulating the OX40 receptor with an agonist antibody we significantly 
delayed tumor progression. However concurrent combination of anti-OX40 and PD-1 
blockade diminished this effect. Along with weakened anti-tumor effect, we noted an acute 
increase in serum cytokines with combination treatment, and heightened expression of T cell 
inhibitory receptors. However, by delaying anti-PD-1 administration, sequential combination 
treatment greatly enhanced the effects of anti-OX40 monotherapy and provided durable 
responses dependent on both CD4+ and CD8+ T cells that eliminated tumors in a substantial 
portion of animals.
Materials and Methods
Mice and Tumor Models
FVB/NJ MMTV-PyMT mice were provided by Emmanuel Akporiaye (Earle. A Chile 
Research Institute (EACRI), Portland, OR). Female FVB/NJ and BALB/c mice of 6–8 
weeks were purchased from Jackson Laboratories. Recognized principles of laboratory 
animal care were followed (Guide for the Care and Use of Laboratory Animals, National 
Research Council, 2011), and all animal protocols were approved by the EACRI Animal 
Care and Use Committee. All mice were maintained in a specific pathogen–free 
environment. For each independent experiment, three tumors from a MMTV-PyMT mouse 
were digested with triple enzymes (Collegenase, DNAase, Hyaluronidase) for 30 minutes 
and resuspended in Matrigel Matrix (Corning) (19,30). 106 cells were orthotopically 
transplanted into the mammary fat pad of naïve FVB/NJ mice (day 0). Seven days later mice 
were randomized and injected intraperitonealy (i.p.) with either 100 μg of anti-OX40 (clone 
OX86), 250 μg anti-PD-1 (clone G4) (7), both (for concurrent treatment), or nothing on days 
7, 9, and 11. Anti-OX40 and anti-PD-1 were a gift from Andrew D Weinberg (EACRI, 
Portland, OR). For sequential combination treatment mice were given anti-OX40 on days 7, 
9, and 11 followed by anti-PD-1 on days 13, 15, and 17. For experiments combining anti-
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OX40 with anti-PD-L1, 200 μg of anti-PD-L1 (clone 10F.962, BioXcell) was substituted for 
anti-PD-1 on the same time course. The 4T1 tumor cell line was a gift of Emmanuel 
Akporiaye (Earle. A Chile Research Institute (EACRI), Portland, OR) in 2010, from stocks 
received from Suzanne Ostrand-Rosenberg (UMBC, Baltimore, MD). Their identity was 
independently confirmed via STR profiling (IDEXX Bioresearch) in 2013, and they were 
mycoplasma negative. All tumor cells were cultured in Complete Media (CM) consisting of 
RPMI-1640 (Lonza) with 1% L-Glutamine (Lonza), 1% Sodium Pyruvate (Lonza), 1% Non-
essential Amino Acids (Lonza), 0.1% Beta Mercaptoethanol, 50 mg Gentimicine Sulfate, 
and 10% fetal bovine serum (Atlas Biologicals Lot # 1070612), and 4T1 cells were passaged 
twice before tumor challenge. 5×103 4T1 tumor cells were transplanted in the mammary fat 
pad of naïve BALB/c mice. Five days later mice were randomized and given anti-OX40, 
anti-PD-1, or both on days 5, 7, and 9 (concurrent) or anti-OX40 on days 5, 7, and 9, 
followed by delayed anti-PD-1 on days 11, 13 and 15. Tumors were measured thrice weekly 
and mice were sacrificed when tumors reached 150mm2 (measured width × length).
CD4/CD8 Depletion
Mice were injected i.p. with 250 μg anti-CD4 (GK1.5, BioXcell), anti-CD8 (53-6.7, 
BioXcell), or rat IgG (BioXcell) twice, one week apart (days 6 and 13 post tumor 
transplant). Mice were analyzed for confirmation of depletion by staining with different 
clones targeting CD4 or CD8 at 1 μg/ml for whole blood, spleen, and tumor.
Serum cytokines
For serum cytokine analysis, whole blood from treated and non-treated, PyMT tumor-
bearing animals was collected on days 9, 11, 13, 14, 17, and 20 post tumor transplant. Serum 
was isolated by 30 minutes incubation at 37°C, 16 hours at 4°C, and 15 minute 
centrifugation at 2400 RCF. Serum was stained with Th1/Th2/Th17 Cytokine Bead Array kit 
(BD Biosciences), and run on an LSRII flow cytometer (BD Biosciences).
Flow Cytometry
Surface and intracellular receptors were measured from single cell suspensions of day 13, 
14, or 19 splenocytes and tumor digest from treated and untreated MMTV-PyMT tumor-
bearing mice. Cells were stained for CD3, CD8, CD4, CD45.1, ICOS, CD137 (4-1BB), 
GITR, PD-1, PD-L1, TIM-3, BTLA, and live/dead. All antibodies were obtained from 
eBioscience, Molecular Probes, or BD Biosciences. Intracellular staining of FoxP3, Ki67, 
Annexin V, IFN-γ, and CTLA-4 was performed with FoxP3 Fixation/Permeabilization kit 
(eBioscience). Samples were run on LRSII Fortessa (BD Biosciences), and analyzed using 
FlowJo software (Treestar). Cells were gated on lymphocytes > singlets > live cells > CD3+ 
> CD4+ or CD8+ for splenocytes or lymphocytes > singlets > live cells > CD45.1+ > CD3+ > 
CD4+ or CD8+ for TIL.
Polyoma Middle T antigen purification and T cell assays
Lysates of an MMTV-PyMT-derived tumor cell line, FAT, were run over anti-PyMT (PyMT, 
Abcam Cat # ab15085)-cross-linked magnetic beads using the Pierce Crosslink Magnetic 
IP/Co-IP Kit (Thermo). The second elution was used and PyMT protein was confirmed via 
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SDS-PAGE and western blot with anti-PyMT. Tumor-bearing treated and untreated day 19 
splenocytes were pooled and expanded as previously described by our laboratory (31) for 48 
hours at 2 × 106 cells/mL in CM in 24-well plates with 5 μg/mL of anti-CD3 (clone 2c11), 
followed by 72 hours at 2 × 105 cells/mL in CM with 60 IU/mL of Interleuken-2 (IL-2, 
Chiron), all at 37 °C. Expanded T cells were cultured with PyMT-loaded APCs. For APC 
loading, naïve, FVB/NJ splenocytes were cultured for 6 hours in CM with either no 
(neutralized elution buffer), 1 μg/mL, or 10 μg/mL of PyMT protein and then co-cultured 1:1 
with 106 expanded T cells. After 24 hours supernatants were assayed by ELISA using 
purified rat anti-mouse IFN-γ antibodies at 2 μg/mL, rat anti-mouse anti-IFN-γ biotin-
labeled antibodies at 1 μg/mL, Streptavidin HRP (BD Biosciences), and SureBlue TMB 
substrate (KPL). Absorbance at 450 nm was read on a Wallac Victor2 plate reader. IFN-γ 
concentration was determined by linear regression using WorkOut 2.5 software 
(PerkinElmer).
Statistical Analysis
All statistical analysis was performed using Gehan-Breslow-Wilcoxon test (survival) or one-
way ANOVA with Tukey’s or Dunnett’s multiple comparison tests (tumor growth, 
phenotype comparisons). All statistics were done with Prism 6 (Graph Pad Software). In 
figure 4C one outlier data point was thrown out of the No Treatment group due to an error in 
cell counting.
Results
Concurrent PD-1 blockade diminishes the therapeutic efficacy of OX40 costimulation
Given previous reports of anti-tumor effects with monotherapy of either anti-OX40 or anti-
PD-1 antibodies, we sought to evaluate the therapeutic efficacy of combination therapy in 
murine mammary cancer models. We utilized an orthotopically-transplanted mammary 
tumor model where spontaneous tumors generated from FVB/NJ MMTV-PyMT transgenic 
mice were transplanted into naïve FVB/NJ hosts. Before treatment, 7 days post transplant, 
OX40 expression in the tumor was predominantly on CD4+FoxP3+ Treg cells, although some 
conventional CD4+FoxP3− and CD8+ cells also expressed OX40 (Figure 1A, 1B). 
Alternatively, PD-1 expression was only identified on intratumoral CD4+FoxP3− and CD8+ 
cells (Figure 1A, 1C). We noted very few T cells expressing both receptors. T cells in the 
draining lymph node and spleen were not PD-1+ and only Treg cells expressed OX40, 
although at a lower frequency than in the tumor (Figure 1A, 1B, 1C). Beginning on day 7, 
tumor-bearing mice (average tumor size of ~6–9 mm2) were treated with three doses of 
either an agonist antibody targeting OX40 (anti-OX40), a blocking antibody targeting PD-1 
(anti-PD-1), or both antibodies on days 7, 9, and 11 (Figure 1E). Mice that received anti-
OX40 treatment exhibited a significant attenuation in tumor growth compared to untreated 
mice, while anti-PD-1 had no impact on tumor growth (Figure 1F). However when anti-
OX40 was combined with anti-PD-1, instead of increasing therapeutic efficacy, we noted a 
significant reduction in tumor control compared to anti-OX40 alone. Survival was also 
significantly diminished in mice receiving combination therapy compared to anti-OX40 
alone (Figure 1G). These data indicate that anti-PD-1 fails to improve the therapeutic 
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efficacy provided by anti-OX40, and in fact PD-1 blockade provides an adverse effect on 
anti-OX40-induced therapy in this model.
Concurrent PD-1 blockade and OX40 costimulation increases serum cytokines and 
upregulates T cell inhibitory receptors
A recent publication reported that OX40 costimulation combined with either PD-1 or PD-L1 
blockade leads to excessive Interferon-gamma (IFN-γ) production and loss of parasite 
control in the context of plasmodium infection (32). Considering this as a possible 
mechanism for the reduced efficacy concurrent PD-1 blockade imparted on anti-OX40-
treated mice, we measured the levels of both type 1 and type 2 cytokines in serum from 
tumor-bearing animals during and after antibody treatment. A striking increase in IFN-γ was 
detected during treatment that peaked two days after the last antibody dose in combination-
treated mice compared to mice receiving monotherapy with either agent (Figure 2A). While 
anti-PD-1 alone had a substantial effect on cytokine levels compared to untreated mice, 
combination treatment boosted cytokines 10–100 fold higher than in untreated tumor-
bearing mice. Serum levels of other cytokines, including IL-6 as well as both type 1 (TNF-
α) and type 2 (IL-4 and IL-10) cytokines were also highly elevated in the combination-
treated group compared to anti-OX40 alone (Figure 2A). Consistent with symptoms of 
cytokine release syndrome or a cytokine storm-like event, combination-treated mice also 
exhibited ruffled, unkempt fur and lethargy from days ~9–14. Untreated mice had minimal 
or undetectable levels of all cytokines. Intriguingly we saw consistent patterns in the kinetics 
of specific types of cytokines over time. Type-2 cytokines IL-4 and IL-10 in combination-
treated mice peaked early, only two days after the first antibody dose, followed by a gradual 
decline but a late increase nine days after the last antibody dose. At the same time, type-1 
cytokines TNF-α and IFN-γ increased during the treatment period, with TNF-α peaking 
first, and then declined after the last antibody dose. Together these data demonstrate that 
simultaneously stimulating the OX40 receptor and blocking the PD-1 receptor can have 
profound effects on the cytokine milieu, drastically increasing the acute cytokine release 
stimulated by anti-PD-1 monotherapy.
We noted splenomegaly in tumor-bearing mice treated with the combination of anti-OX40 
and anti-PD-1 (Supplementary Figure 1A). Splenocyte numbers increased after just a single 
dose of combination antibodies at day 9, and steadily grew over time to significantly outpace 
untreated or monotherapy treated mice, peaking at day 17 (Supplementary Figure 1B). 
Given the substantial increase in serum cytokines and this splenomegaly, we investigated 
whether combination treatment associated with an increase in peripheral T cell activation 
induced cell death (AICD) or apoptosis. Combination treatment increased the frequency of 
Annexin V+ cells that also stained positive with Propidium Iodide (PI, Live/Dead), marking 
them as dead, apoptotic cells, in both the CD4+ and CD8+ T cell splenic compartment 
(Supplementary Figure 1C, 1D).
T cell activation and inhibition is a delicate balance of positive and negative signals that 
involves a host of transiently and constitutively expressed surface receptors, some of which 
are compensatory and other independent of each other. With the amplified levels of IFN-γ 
and other cytokines observed in the serum of combination-treated mice, we anticipated 
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substantial changes to T cell surface receptor expression. Similar to previous reports (33), 
we found that a majority of untreated splenic T cells expressed PD-L1 on day 13 and 
treatment further increased the frequency of PD-L1+ T cells (Supplementary Figure 2A, 2B). 
IFN-γ upregulates PD-L1 and after combination treatment we observed a significant 
increase in PD-L1 fluorescence intensity on both CD4+ and CD8+ T cells (Supplementary 
Figure 2C, 2D). The frequency of intratumoral CD8+ T cells expressing inhibitory receptors 
T cell immunoglobulin and mucin-domain containing-3 (TIM-3) or CTLA-4 were also 
increased with anti-PD-1 or combination treatment, with more than double the frequency of 
TIM-3+ cells compared to anti-OX40 monotherapy (Figure 2B). The prevalence of 
CTLA-4+CD4+ cells also increased in all treatment groups, but there were no changes to 
TIM-3+CD4+ cells with treatment (Figure 2B). In the spleen however, there were significant 
increases in the frequencies of both CTLA-4+ and TIM-3+ cells in both the CD4+ and CD8+ 
compartments with combination treatment (Figure 2C). B and T Lymphocyte Attenuator 
(BTLA) is another inhibitory marker initially expressed on activated T cells, but subsequent 
downregulation (BTLA−) is associated with terminal T cell differentiation in the tumor and a 
decreased capacity to proliferate (34). With combination treatment, BTLA+ T cells were 
significantly decreased in both the CD4+ and CD8+ T cell populations of the spleen (Figure 
2D, 2E). The frequency of cells expressing costimulatory molecules Inducible T cell 
costimulator (ICOS), 4-1BB (CD137), or Glucocorticoid-induced TNFR-related protein 
(GITR) in the tumor were not altered with any treatment (Supplementary Figure 3A, 3B). 
However in the spleen, combination treatment significantly increased the prevalence of 
ICOS+ and 4-1BB+ cells in both the CD4+ and CD8+ compartment (Supplementary Figure 
3C, 3D). Thus combination treatment appears to primarily impact CD8+ T cells in the tumor, 
but both CD4+ and CD8+ T cells in the periphery. These data suggest that concurrent anti-
OX40 and anti-PD-1 combination treatment impacts peripheral T cells more than either 
agent alone. But importantly combination treatment increases the frequency of exhausted T 
cells in the tumor compared to anti-OX40 monotherapy.
Concurrent combination therapy increases the frequency of proliferating T cells in the 
tumor
Given the suggestion that combination treatment increased exhaustion in TIL, we next 
investigated the composition and proliferation of intratumoral T cells. Two days after the 
completion of treatment (day 13 post tumor transplant), anti-OX40-treated tumors had an 
increased frequency of CD3+ T cells compared to untreated tumors (Figure 3A). T cell 
frequency was further increased with the addition of anti-PD-1. The predominant population 
of T cells in treated or untreated tumors were CD4+ cells, specifically CD4+FoxP3− 
conventional T cells (Figure 3B). However, only anti-OX40 monotherapy caused a 
significant increase in the total number of CD4+FoxP3− conventional and CD4+FoxP3+ Treg 
T cells infiltrating the tumor, while CD8+ T cells were unchanged (Figure 3C). Neither 
antibody resulted in a significant depletion of Treg cells. Given an attenuated therapeutic 
effect (Figure 1D, 1E), unexpectedly combination treatment significantly increased the 
frequency of both Ki67+ proliferating CD4+FoxP3− and CD8+ T cells (Figure 3D). The 
prevalence of proliferating CD4+FoxP3+ Treg cells were significantly increased with 
combination compared to anti-PD-1 monotherapy or no treatment, but not anti-OX40 
treatment. While combination treatment increases proliferation of TIL at this time point, the 
Messenheimer et al. Page 7
Clin Cancer Res. Author manuscript; available in PMC 2018 October 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
increase in TIM-3 expression (Figure 2B) and loss of BTLA expression (Figure 2D, 2E) 
suggests that this effect may be short lived and this metric does not correlate with 
therapeutic response. Thus we investigated alternative ways to successfully combine OX40 
costimulation with PD-1 blockade.
Sequential, delayed PD-1 blockade augments anti-OX40 anti-tumor effects
Given the diminished anti-tumor effects generated by the concurrent combination of anti-
OX40 and anti-PD-1 and the knowledge that PD-1 plays a critical role in the contraction 
phase of a normal immune response, we reasoned that combination treatment with anti-PD-1 
antibody would be more effective if it was given after the initial T cell boost generated by 
anti-OX40. In support of this hypothesis, we noted a significant increase in PD-1 expression 
on day 13 splenic CD4+ and CD8+ T cells after anti-OX40 treatment (Figure 4A). 
Accordingly anti-OX40 given on days 7, 9, and 11-post tumor transplant, was followed by 
delayed anti-PD-1 administered on days 13, 15, and 17, providing a sequential treatment 
(Figure 4B). This sequential treatment resulted in a significant delay in tumor growth 
compared to anti-OX40 alone with some tumors reaching complete regression (Figure 4C). 
Sequential combination therapy was also far superior to concurrent combination therapy. 
Delayed anti-PD-1 treatment alone had no significant impact on tumor growth 
(Supplementary Figure 4A). Anti-OX40 plus delayed anti-PD-1 correspondingly resulted in 
a significant increase in survival, with ~30% of the animals experiencing complete 
regression of their tumors (200+ days) (Figure 4D).
To establish that the specific order of sequential treatment was crucial, we reversed the 
combination, giving anti-PD-1 first, followed by delayed anti-OX40. This treatment proved 
to be much less effective than anti-OX40 plus delayed anti-PD-1, demonstrating that 
providing OX40 costimulation first and then blocking the PD-1 receptor is critical to the 
effects of sequential combination therapy (Figure 4E). We confirmed these results in the 
poorly immunogenic, faster growing 4T1 mammary tumor model. While therapeutic 
efficacy was not as profound as in the MMTV-PyMT model, sequential combination 
treatment provided significant tumor growth delay, but concurrent combination had no effect 
on tumor growth (Supplementary Figure 5A). The reversed sequence results were also 
confirmed in the 4T1 model (Supplementary Figure 5B).
Despite possible differences in mechanism, targeting the PD-1 receptor or its ligand PD-L1 
for immunotherapeutic intervention has shown similar results in the clinic (3,35). To 
investigate whether timing was also critical for anti-OX40 combination with PD-L1 
blockade, we compared two treatment strategies, concurrent or sequential combination of 
anti-OX40 and anti-PD-L1. Anti-PD-L1 alone provided a short but significant delay to 
tumor progression, differentiating it from anti-PD-1 treatment (Supplementary Figure 4B, 
Figure 1D). However in combination, sequential anti-OX40 and anti-PD-L1 treatment 
delayed tumor growth for a longer period or time compared to concurrent combination (p = 
0.05, Figure 4F). These data establish that sequential combination of anti-OX40 with PD-1 
pathway blockade provides superior therapy to concurrent combination in two different 
preclinical mammary cancer models.
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Sequential anti-OX40 and anti-PD-1 combination therapy maintains proliferating T cells 
and reduces T cell exhaustion
Unlike 6 days earlier, when concurrent combination treatment increased TIL proliferation 
(Figure 3D), on day 19 (two days after the final sequential anti-PD-1 dose) concurrent 
combination treatment resulted in a significant reduction in the frequency of Ki67+ 
proliferating CD4+FoxP3− and CD8+ T cells in the tumor (Figure 5A, 5B). However this 
drop in proliferation did not occur with sequential combination treatment. Additionally at 
day 19, we noted significantly more BTLA+ CD4+ and CD8+ T cells in the tumor with 
sequential combination treatment (Figure 5C, 5D). The large spikes in multiple serum 
cytokines induced by concurrent anti-OX40 and anti-PD-1 led us to investigate cytokine 
levels following sequential combination therapy. We compared the levels of IFN-γ and 
TNF-α after completion of concurrent combination or anti-OX40 alone (day 13) and 
sequential combination (day 19) and again noted very high levels of both cytokines in 
concurrent combination animals on day 13 (Supplementary Figure 6A, 6B). However, 
sequential combination treatment did not induce high levels of either cytokine at the earlier 
(anti-OX40 only) or later time points. Additionally, the frequency of CD8+ T cells 
expressing TIM-3 in the concurrent combination-treated tumors at day 19 remained at 
similar frequencies as day 13, but importantly, the sequential addition of anti-PD-1 to anti-
OX40 did not increase this population of exhausted cells compared to anti-OX40 
monotherapy (Figure 5E). CTLA-4 expression was the opposite, with increased frequencies 
of CTLA-4+ cells associating with the improved responses of anti-OX40 monotherapy and 
sequential combination (Figure 5E). Patterns of expression on CD8+ T cells in the spleen 
were similar, but at much lower frequencies (Figure 5F). At this later time point, the 
frequency of T cells expressing costimulatory molecules were not significantly altered by 
sequential combination treatment in the tumor or spleen (Supplementary Figure 7). 
Combined these data demonstrate that concurrent combination treatment induces a strong, 
but short-lived burst of intratumoral T cell proliferation, which coincides with acute cytokine 
secretion, increased TIM-3+CD8+ exhausted cells, and attenuated anti-tumor effect (Figure 
1E, 1F). But administering anti-OX40 and anti-PD-1 in a sequential fashion maintains less 
differentiated, BTLA+ T cells, sustains proliferation in the tumor, and drastically reduces the 
TIL exhaustion induced by concurrent combination treatment.
To evaluate whether combination treatment increased the T cell response to a specific tumor-
associated antigen, we purified whole protein of the viral oncogene polyoma middle T 
antigen (PyMT) from an MMTV-PyMT-derived cell line previously established in our 
laboratory (Supplementary Figure 8A). We loaded whole protein onto antigen presenting 
cells (APCs) and stimulated anti-CD3/IL-2 expanded splenocytes from day 19 tumor-
bearing mice treated with concurrent or sequential combination therapy. T cells from 
untreated MMTV-PyMT-bearing mice generated a T cell response against PyMT, identified 
by secretion of IFN-γ after stimulation with PyMT-loaded APCs (Supplementary Figure 
8B). As expected, sequential combination immunotherapy with anti-OX40 followed by anti-
PD-1 increased the IFN-g response to PyMT; however, the magnitude of this response was 
the same as that observed for mice treated with anti-OX40 and anti-PD-1 concurrently.
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Anti-tumor effect of sequential anti-OX40 and anti-PD-1 combination requires both CD4+ 
and CD8+ T cells for optimal therapeutic effect
Given the contribution that CD4+ T cells can have to T cell help and the high prevalence of 
CD4+FoxP3− T cells in MMTV-PyMT tumors (Figure 3B, 3C), we sought to evaluate the 
prevalence and necessity of CD4+ and CD8+ T cells in the anti-tumor effect provided by 
sequential combination treatment. Phenotyping tumor infiltrating T cells in sequential 
combination-treated tumors on day 19 (two days after the final anti-PD-1 dose), we noted 
conventional CD4+FoxP3− T cells still made up a majority of the T cells in treated tumors 
(Figure 6A). To assess the role of different T cell populations, either CD4+ depleting, CD8+ 
depleting, or rat IgG non-depleting antibodies were injected on days 6 and 13 into MMTV-
PyMT tumor-bearing mice before both anti-OX40 (beginning on day 7) and anti-PD-1 
(beginning on day 13) were administered. CD4+ T cell depletion led to a significant increase 
in tumor infiltrating CD8+ T cells in sequential combination treated tumors (Figure 6B), but 
despite this increase, CD4+ T cell ablation completely eliminated the therapeutic efficacy 
provided by sequential combination, proving their necessity for the combination treatment 
(Figure 6C). CD8+ T cells were also necessary for the observed therapeutic efficacy (Figure 
6D). Although initially the therapeutic effect was unaltered, loss of tumor control became 
apparent at later time points (after day 30). Consequently, depletion of either CD4+ or CD8+ 
T cells in combination treated mice reduced animal survival, although CD8+ depleted mice 
had significantly longer survival than CD4+ depleted or untreated animals (Figure 6E). 
These data strongly indicate that while conventional CD4+ T cells play a major and 
necessary role in the immediate tumor control provided by sequential anti-OX40 plus anti-
PD-1, CD8+ T cells are also necessary for long-term anti-tumor effect.
Discussion
Questions of timing and sequence are important aspects of study design when 
complementing chemotherapy, radiotherapy, or targeted therapies, but as novel 
immunotherapies continue to demonstrate significant clinical impact it will be important to 
design treatment regimens that recognize and optimize compensatory, regulatory, and 
homeostatic immune mechanisms. Recent trials have focused on combined checkpoint 
blockade, but agents that target costimulatory molecules such as OX40 offer a promising 
approach to augment the effect of current immunotherapies targeting inhibitory receptors 
like PD-1. Treatments combining T cell-targeting antibodies with vaccines, adoptive T cell 
transfer, and targeted therapies are also being extensively explored preclinically (36–40). 
However, the designs of these types of studies are often empirical and take a straightforward 
additive approach that may not be optimal considering the unique immunological 
mechanisms that influence combination treatments. While others have demonstrated that 
administering checkpoint blockade “late” or for a longer duration than costimulatory 
antibodies is beneficial with preclinical combination immunotherapies (41,42), to our 
knowledge ours is the first report to directly compare concurrent combination treatment with 
non-overlapping, sequential treatment with the same agents. Given that a substantial portion 
of patients does not respond to PD-1 blockade (in monotherapy or in combination) (1,3), our 
findings in anti-PD-1 refractory model systems suggest that the use of costimulatory 
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stimulation may impact these patients. PD-1 blockade could then be combined in a 
sequential manner to boost T cell activation with anti-OX40 costimulation.
Currently multiple OX40 targeted antibodies have been developed with humanized IgG1 
(increasing the possibility of antibody-dependent cell-mediated cytotoxicity (ADCC) and 
Treg cell depletion) or IgG2 isotypes and are in phase one clinical trials as monotherapies 
(NCT01644968, NCT02221960, NCT02318394, NCT01416844, NCT02274155) or in 
combination with anti-CTLA-4 (NCT01689870), anti-PD-L1 (NCT02205333, 
NCT02410512, NCT02528357), or anti-4-1BB (NCT02315066). Additionally anti-OX40 is 
also being investigated in combination with radiation therapy (NCT01303705, 
NCT01862900). As clinical trials employing antibodies targeting other costimulatory 
molecules such as GITR and 4-1BB are currently being initiated, some in combination with 
checkpoint blockade, understanding not just which T cell costimulatory or inhibitory 
molecules to target but when to stimulate or block them is likely to be a critical component 
of an optimal therapeutic regimen. Our group highlighted this concept in a recent paper 
demonstrating the importance of timing when anti-CTLA-4 or anti-OX40 is combined with 
radiation (19).
In a model of B cell lymphoma, McKee et al. recently demonstrated an abrogation of the 
therapeutic effect of 4-1BB costimulation when anti-PD-1 was combined concurrently (43). 
In our studies, concurrent anti-OX40 and anti-PD-1 also attenuated anti-OX40-induced 
therapeutic efficacy, dramatically increased serum cytokine levels, and increased peripheral 
T cell apoptosis. A previous report noted reduced gene expression of BTLA in T cells 
treated with anti-OX40 and anti-PD-L1 (8). Similarly, we noted a significant decrease in the 
frequency of BTLA+ peripheral T cells after concurrent combination treatment. Others have 
suggested that BTLA− cells are less effective in the tumor, with reduced proliferative 
capacity and decreased responsiveness to costimulatory molecules (34). We also observed 
reduced proliferation in concurrent combination-treated T cells in the tumor seven days after 
the conclusion of treatment (Figure 5A, 5B), despite an increase in proliferation six days 
prior (Figure 3D). We reason that concurrent combination of anti-OX40 and anti-PD-1 
negatively increases T cell differentiation, indicated by loss of BTLA expression. Despite 
their initial burst of proliferation, terminally differentiated cells are less proliferative long-
term, making them less effective at mediating tumor destruction. Differentiation status of T 
cells is a key determinant of T cell-mediated anti-tumor responses, and increased success of 
adoptive T cell transfer has been linked with less differentiated cells that maintain higher 
proliferative capacity (44,45). Notably, we have demonstrated here that by administering 
combination treatment in a sequential manner we can reduce terminal differentiation, 
maintain proliferation, and provide a more substantial anti-tumor effect compared to 
concurrent combination treatment.
In addition to a lower frequency of peripheral T cells expressing BTLA, the frequency of 
intratumoral CD8+ T cells expressing the inhibitory receptor TIM-3 were also significantly 
amplified with concurrent combination treatment. CD8+ T cells that express both TIM-3 and 
PD-1 are commonly recognized as exhausted, with reduced proliferative capacity and 
effector function (46). Deeply exhausted and terminally differentiated T cells can also more 
frequently undergo AICD and apoptosis (47,48). Importantly TIM-3+CD8+ T cells were less 
Messenheimer et al. Page 11
Clin Cancer Res. Author manuscript; available in PMC 2018 October 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
frequent in tumors treated with anti-OX40 monotherapy or sequential combination, 
suggesting a less exhausted phenotype, and these treatments associated with the best anti-
tumor responses (Figure 4C, 4D). With concurrent combination immunotherapies capable of 
inducing an acute cytokine response, the risk of “whack-a-mole”, where one therapeutic 
target is neutralized but one or more other inhibitory receptor like TIM-3 pops up, is a very 
real possibility, supported by our data with the concurrent combination of anti-OX40 and 
anti-PD-1. However this also presents possible targets for other agents specific to these 
inhibitory receptors, as well as possible biomarkers to monitor the success of combination 
treatments in generating an appropriate milieu to support a therapeutic anti-cancer immune 
response. In support of this concept, Koyama et al. noted “adaptive resistance” with 
upregulated expression of TIM-3 on TIL in anti-PD-1 resistant tumors and demonstrated 
improved responses with secondary TIM-3 blockade (49). Although some have recently 
suggested that PD-1+TIM-3+ deeply exhausted or hyper-exhausted T cells are potentially 
unrecoverable, and may not be impacted by checkpoint blockade (50,51).
A previous report noted a synergistic anti-tumor effect with concurrent combination of anti-
OX40 and anti-PD-1 (52). The ID8 ovarian tumor used was impervious to anti-OX40 or 
anti-PD-1 monotherapy. It is important to remember that in our transplanted MMTV-PyMT 
model the therapeutic effect of concurrent combination, although inferior to sequential 
combination and anti-OX40 monotherapy, was not completely abrogated and did have a 
significant effect on tumor growth (Figure 1F, 1G). Other publications using the ID8 model, 
show that anti-PD-L1 monotherapy significantly increases survival, and this effect was not 
significantly augmented when anti-4-1BB was added in combination (41,53). Combined, 
these reports strongly suggest that ID8 is not responsive to costimulation (anti-OX40 or 
anti-4-1BB), and this may be a key difference between the results in our models and ID8 that 
have implications in the clinic. Transplanted MMTV-PyMT tumors have a much higher 
frequency of CD4+ T cells compared to CD8+ T cells. It’s also well documented that OX40 
expression is more common on CD4+ cells than CD8+ cells, which we have confirmed in the 
MMTV-PyMT tumors (Figure 1A, 1B). This provides a possible explanation why OX40 
monotherapy generates a therapeutic effect in the MMTV-PyMT model, but not the ID8 
model, which was more dependent on CD8+ T cells for therapeutic response. Perhaps 
patients with high frequencies of CD4+ TIL may be more likely to respond to anti-OX40. 
Sequential combination treatments with costimulation and checkpoint blockade may then be 
most critical to patients who have some initial response to costimulation. Alternatively, 
perhaps in patients who do not respond to either costimulation or checkpoint blockade a 
concurrent combination may be more effective by inducing a strong cytokine response and 
initial burst of proliferation as we see in our preclinical models.
CD4+ T cells can provide cytokine support to “help” CD8+ T cells, but have also 
demonstrated cytotoxic capabilities (54,55). Conflicting reports over the necessary 
contribution of CD4+ and CD8+ T cells for therapeutic benefit in the MMTV-PyMT model 
have been published, with one reporting CD4+ T cells to be dispensable and in fact 
detrimental (56) and another suggesting that CD8+ T cells are dispensable while 
conventional CD4+ T cells are necessary (57). Our findings, showing a variance in the 
timing of necessary T cell populations, provide a possible explanation for these 
discrepancies. While myeloid-targeted therapies may require CD8+ T cells at early time 
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points (30), some T cell-targeted therapies may not. Transient regulatory T cell ablation does 
not require CD8+ T cells (57), but alone this therapy only slows tumor growth for a limited 
period of time before continued progression. Sequential anti-OX40 plus anti-PD-1 provides 
a much longer period of stable disease, with some tumors reaching full regression. Given 
that OX40 is expressed almost exclusively on intratumoral CD4+ T cells in this model, it 
shouldn’t be surprising that an anti-OX40-generated effect would require CD4+ T cells, even 
when the PD-1 pathway is also targeted. In support of this, when treated tumors were 
depleted of CD4+ cells, even a significant increase in CD8+ TIL had no effect on tumor 
growth. Alternatively, CD8 depletion saw initial tumor growth delay, followed by rapid 
progression, indicating that the early anti-tumor effect provided by sequential combination 
treatment is in fact independent of CD8+ T cells, but these cells are necessary for a durable 
memory response. We hypothesize that since few CD8+ TIL express OX40 at the time of 
anti-OX40 treatment and the early anti-tumor effects are dependent only on CD4+ T cells, 
the “help” provided by anti-OX40-stimulated CD4+ T cells drives CD8+ cells to long-term 
functionality and makes them necessary for long-term tumor regression. Consistent with this 
hypothesis, others have demonstrated that anti-OX40 combined with delayed anti-PD-L1 (1 
and 3 days post anti-OX40) treatment saw a boost in T cell function when antigen-specific 
CD8+ T cells were transferred with CD4+ help (8). Clearly long-term therapeutic efficacy 
targeting OX40 and PD-1 in this model requires both CD4+ and CD8+ T cells, which 
corroborates a previous report utilizing anti-OX40 in another tumor model (16).
Our results demonstrate that in some tumors the sequence and timing of antibody treatment 
targeting both costimulatory and inhibitory receptors is critical to success of the combined 
therapy. These data offer a strong rationale for delaying PD-1 or PD-L1 blockade or possibly 
other inhibitory receptor-targeted therapies such as CTLA-4, TIM-3, or LAG-3 until after 
costimulation has boosted the tumor-specific T cells to a state where checkpoints are 
inhibiting the anti-tumor response. Sequential treatment has the combined benefit of both 
optimizing the anti-tumor immune response as well as potentially minimizing possible 
toxicity from acute cytokine release. Given the complex nature of T cell costimulatory and 
inhibitory signaling, our data underscores the delicate balance that the immune system 
maintains and suggests a number of factors that ought to be explored in combination 
immunotherapy clinical trial designs. In our opinion, as these types of combination 
immunotherapy studies move into clinical trials, the importance of characterizing a patient’s 
baseline immunity and assessing the impact of treatment has never been more clear. 
Fortunately, the tools to assess immunity are improving. A recent taskforce reviewed the 
state-of-the-art technologies for performing these analyses (58) and the AACR and FDA 
have been holding a series of policy forums to discuss a vision for developing effective 
combination immunotherapy (59). Together, these joint efforts between industry, academia, 
and regulatory agencies hold promise for the development of a new generation of 
immunotherapies that take advantage of the latest science and technology to further improve 
outcomes for a greater percentage of patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Statement of Translational Relevance
In an attempt to improve the percentage of patients that respond to PD-1 blockade, 
hundreds of studies are combining treatments that block PD-1 signaling with anti-cancer 
drugs or other immunological therapies. Much of the preclinical data supporting these 
studies were generated from immunogenic tumor models that are responsive to 
checkpoint blockade. Using tumor models unresponsive to checkpoint blockade we found 
that simultaneous administration of a T cell agonist with checkpoint blockade reduced 
therapeutic efficacy compared to the agonist alone, but sequencing significantly improved 
therapy and resulted in apparent cure of some animals. While no animal model is a 
perfect surrogate for developing immunotherapy of human cancer, these studies identify 
that the schedule of drug administration can significantly impact therapeutic efficacy and 
suggests some parameters that might be evaluated in early combination clinical trials of 
immunologically active agents.
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Figure 1. Concurrent administration of anti-PD-1 and anti-OX40 reduces anti-tumor effect of 
anti-OX40 alone
(A) Representative flow cytometric quantification of OX40 and PD-1 on conventional 
CD4+FoxP3−, CD8+, and CD4+FoxP3+ T cells in the draining lymph node, spleen, and 
tumor of pretreatment 7 day MMTV-PyMT tumor-bearing mice. (B) Frequency of OX40+ T 
cells. n = 4–5, one representative of two independent experiments. (C) Frequency of PD-1+ 
T cells. (D) Treatment schedule of MMTV-PyMT tumor-bearing mice. Mice were treated on 
days 7, 9, and 11 with either 100 μg. anti-OX40, 250 μg. anti-PD-1, or both antibodies. (E) 
Messenheimer et al. Page 19
Clin Cancer Res. Author manuscript; available in PMC 2018 October 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Mean tumor growth of treated tumors, n = 6, one representative of two independent 
experiments. (F) Kaplan-Meier survival curves of treated mice. n =10–12, combination of 
two independent experiments. Error bars represent SEM. ** = p < 0.01, **** = p < 0.0001
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Figure 2. Concurrent combination of anti-OX40 and anti-PD-1 increases serum cytokines and 
inhibitory receptors on T cells
(A) Time course of serum cytokines taken from MMTV-PyMT tumor-bearing mice treated 
with anti OX40, anti-PD-1, or both antibodies. Black arrows (ê) indicate antibody treatment. 
X-axis represents time post tumor transplant. IFN-γ, TNF, IL-6, IL-10, and IL-4 were 
measured on days 7, 9, 11, 13, 14, 17, and 20 post tumor transplant, n = 4–14, combination 
of five independent experiments. (B, C) Frequency of CD4+ (left) and CD8+ (right) T cells 
expressing inhibitory receptors TIM-3 and CTLA-4 from the tumor (B) or spleen (C) of 
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MMTV-PyMT tumor-bearing mice treated with anti-OX40, anti-PD-1, or both, day 13 after 
tumor transplant. n = 9–14, combination of two-three independent experiments. (D,E) 
Frequency of BTLA+ CD4+ (D) and CD8+ (E) T cells. n = 4–5, one representative of two 
independent experiments. Error bars represent SEM. Stars above single bars represent 
minimum significance compared to all three other groups. * = p < 0.05, ** = p < 0.01, *** = 
p < 0.001, **** = p < 0.0001
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Figure 3. Concurrent combination treatment increases the frequency of proliferating T cells in 
the tumor, but only anti-OX40 increases total TIL
MMTV-PyMT tumor-bearing mice were treated as in Figure 1C and tumors were resected 
on day 13. (A) Flow cytometric quantification of the frequency of CD3+ T cells of the 
CD45+ cell population in treated tumors. (B) Average T cell populations as a frequency of 
CD45+CD3+ cells in the tumor. (C) Total conventional CD4+FoxP3− (top), CD4+FoxP3+ 
Treg (middle) and CD8+ (bottom) T cells in untreated and treated tumors. Normalized by 
mm2 per tumor. (D) Frequency of Ki67+ proliferating conventional CD4+FoxP3− (top), 
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CD4+FoxP3+ Treg (middle) and CD8+ (bottom) T cells in the tumor. n = 7–10, combination 
of two independent experiments. Error bars represent SEM. * = p < 0.05, ** = p < 0.01, *** 
= p < 0.001, **** = p < 0.0001
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Figure 4. Sequential combination treatment augments anti-OX40 therapeutic efficacy
(A) Frequency of PD-1 expression on conventional CD4+ (left) and CD8+ (right) T cells in 
day 13 MMTV-PyMT tumor-bearing spleens after anti-OX40 therapy. n = 5, one 
representative of four independent experiments. (B) Treatment schedule of MMTV-PyMT 
tumor-bearing mice comparing concurrent and delayed (delay, d), sequential therapy. 
Delayed anti-PD-1 was given on days 13, 15, and 17. (C) Mean tumor growth of treated 
tumors, n = 6, one representative of two independent experiments is shown. (D) Survival of 
combination treated mice. n = 10–12, combination of two independent experiments. (E) 
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Mean tumor growth of tumors treated sequentially with anti-OX40 then anti-PD-1 or anti-
PD-1 then anti-OX40. n = 6, one representative of two independent experiments is shown. 
(F) Mean tumor growth of MMTV-PyMT tumor-bearing mice treated with a combination of 
anti-OX40 plus 200 μg. of either concurrent (days 7, 9 and 11) or delayed (days 13, 15, and 
17) anti-PD-L1, n = 5–6, one representative of two independent experiments is shown. Error 
bars represent SEM. * = p < 0.05, *** = p < 0.001, **** = p < 0.0001
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Figure 5. Sequential combination treatment maintains proliferating T cells and avoids increases 
in inhibitory receptors
MMTV-PyMT tumor-bearing mice were treated as in Figure 4B, and tumor and spleens 
were resected at day 19 (two days after last delayed PD-1 treatment). (A,B) Frequency of 
Ki67+ proliferating conventional CD4+FoxP3− (A) and CD8+ (B) T cells from tumors. n = 
9–10, combination of two independent experiments. (C,D) Frequency of BTLA+ CD4+ (C) 
and CD8+ (D) T cells from tumors. n = 4–5, one representative of two independent 
experiments. (E,F) Frequency of CD4+ (left) and CD8+ (right) T cells expressing TIM-3 and 
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CTLA-4 from the tumor (E) or spleen (F). n = 8–14, combination of two (E) or three (F) 
independent experiments. Error bars, SEM. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, 
**** = p < 0.0001
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Figure 6. Sequential combination treatment requires both CD4+ and CD8+ T cells for optimal 
therapeutic effect
MMTV-PyMT tumor-bearing mice were treated with anti-OX40 plus delayed anti-PD-1 
(PD-1d), combined with 250 μg. anti-CD4, anti-CD8, or rat IgG on days 6 and 13 (A) 
Average T cell populations as a frequency of CD45+CD3+ cells in non-depleted day 19 
treated and untreated tumors. n = 8–9, combination of two independent experiments. (B) 
Quantification of total CD8+ cells per mm2 of tumor on day 20–21 determined via flow 
cytometry. n = 4, combination of two independent experiments. (C–E) Mean tumor growth 
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of combination treated CD4-depleted (C) or CD8-depleted (D) mice. n = 9–10, one 
representative of two independent experiments shown. (E) Survival of CD4 or CD8-depleted 
mice. n = 18–20, combination of two independent experiments. Error bars represent SEM. * 
= p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001
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